SU therapy is effective in the treatment of hyperglycemia in patients with NDM who have a mutation in KCNJ11 or ABCC8. Up to 90–95% of patients with NDM caused by mutations in these genes can cease insulin therapy after initiation of SU therapy (3, 5). This evidence concerns the gene INS and neonatal diabetes mellitus.